Geoff Meacham is ranked #1882 on 13Foresight, scored on hit rate, average return versus the market, and number of calls.

Analyst Tracker/Geoff Meacham

Citi

Geoff Meacham

Q: How accurate are Geoff Meacham's stock ratings?

About 57% of Geoff's ratings were profitable over a one-year hold, with an average return of +3.7% per rating, measured by 13Foresight from historical prices.

Citi

Wall Street Analyst

★★★☆☆

#1882

on 13Foresight · ranked by our own returns

57%

Success Rate

+3.6%

Average Return

133 of 233 calls profitable · -74.2% vs benchmark

Time Frame ⓘ

1 Yr 2 Yr 3 Yr 5 Yr

Compared To ⓘ

S&P 500 (SPY)

🔒 3-year track record is Pro. Showing 1-year — upgrade.

📈 Across the calls we could measure, roughly 57% of Geoff Meacham's ratings turned a profit when each position was held for 1 year — averaging +3.6% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

173 Buy 119 Hold 9 Sell

Geoff's Stock Coverage 80 ratings · 2026-11-14

Company	Date	Position	Consensus ⓘ	Price Target ⓘ	1-Yr Return	vs S&P 500 ⓘ
ABOS Acumen Pharmaceuticals	Oct 30, 2026	HOLD	Buy +3291.3% avg upside 10 analysts	$1.00 375.94% Upside	-4.8%	·
REGN Regeneron	Oct 30, 2026	HOLD	Strong Buy -12.1% avg upside 60 analysts	$825.00 11.03% Downside	+3.0%	·
GILD Gilead Sciences	Oct 30, 2026	BUY	Strong Buy -27.3% avg upside 66 analysts	$188.00 10.16% Upside	-1.5%	·
LLY Eli Lilly & Co	Oct 30, 2026	BUY	Strong Buy -16.7% avg upside 50 analysts	$1650.00 16.33% Upside	+0.7%	·
KYMR Kymera Therapeutics	Oct 29, 2026	BUY	Strong Buy -9.6% avg upside 39 analysts	$150.00 18.48% Upside	+4.0%	·
BIIB Biogen	Oct 29, 2026	HOLD	Strong Buy +6.6% avg upside 53 analysts	$255.00 0.62% Upside	+1.5%	·
AMGN Amgen	Oct 27, 2026	HOLD	Buy -29.9% avg upside 57 analysts	$405.00 13.09% Downside	+4.3%	·
JAZZ Jazz Pharmaceuticals	Oct 27, 2026	BUY	Strong Buy +16.2% avg upside 36 analysts	$325.00 50.45% Upside	+16.8%	·
BNTX BioNTech SE	Oct 27, 2026	BUY	Strong Buy +48.9% avg upside 28 analysts	$125.00 41.78% Upside	-2.6%	·
MRNA Moderna	Oct 27, 2026	SELL	Hold -48.5% avg upside 38 analysts	$80.00 63.84% Downside	-7.4%	·
VRTX Vertex Pharmaceuticals	Oct 27, 2026	BUY	Strong Buy -20.5% avg upside 62 analysts	$585.00 4.74% Upside	+5.2%	·
PFE Pfizer	Oct 27, 2026	HOLD	Buy +9.2% avg upside 46 analysts	$27.00 11.58% Downside	-0.1%	·
MRK Merck & Company	Oct 27, 2026	HOLD	Strong Buy -3.5% avg upside 44 analysts	$145.00 3.12% Downside	+3.6%	·
ABBV AbbVie	Oct 20, 2026	HOLD	Strong Buy -14.5% avg upside 47 analysts	$260.00 11.93% Downside	+2.1%	·
MANE Veradermics, Incorporated	Oct 19, 2026	BUY	Strong Buy +9.8% avg upside 7 analysts	$160.00 14.44% Upside	+6.0%	·
AMLX Amylyx Pharmaceuticals Inc	Oct 16, 2026	BUY	Strong Buy +31.6% avg upside 14 analysts	$39.00 35.05% Upside	+15.0%	·
NVAX Novavax	Oct 16, 2026	SELL	Buy +130.1% avg upside 20 analysts	$8.00 20.68% Downside	·	·
KNSA Kiniksa Pharmaceuticals	Oct 15, 2026	BUY	Strong Buy -11.0% avg upside 12 analysts	$100.00 8.46% Upside	+18.9%	·
NAMS NewAmsterdam Pharma Company	Oct 15, 2026	BUY	Strong Buy +136.0% avg upside 19 analysts	$55.00 174.13% Upside	-2.3%	·
VOR Vor Biopharma	Oct 15, 2026	BUY	Buy +117.7% avg upside 19 analysts	$50.00 154.14% Upside	+0.4%	·
FTH Faeth Therapeutics	Oct 15, 2026	BUY	Strong Buy +160.3% avg upside 22 analysts	$55.00 194.21% Upside	+7.0%	·
NUVB Nuvation Bio	Oct 15, 2026	BUY	Strong Buy +178.0% avg upside 18 analysts	$12.00 152.15% Upside	-16.0%	·
SRRK Scholar Rock Holding	Oct 15, 2026	BUY	Strong Buy +48.3% avg upside 23 analysts	$74.00 68.59% Upside	+6.3%	·
PTGX Protagonist Therapeutics	Oct 15, 2026	BUY	Strong Buy -17.0% avg upside 19 analysts	$182.00 25.62% Upside	-4.1%	·
BMY Bristol-Myers Squibb	Oct 13, 2026	HOLD	Buy -2.2% avg upside 42 analysts	$70.00 12.12% Upside	+9.9%	·
RPRX Royalty Pharma	Oct 12, 2026	BUY	Strong Buy -12.2% avg upside 15 analysts	$70.00 4.14% Upside	+20.0%	·
PTCT PTC Therapeutics	May 07, 2026	HOLD	Buy +35.4% avg upside 29 analysts	$75.00 25.14% Upside	-1.6%	·
JNJ Johnson & Johnson	Jun 10, 2024	HOLD	Strong Buy -9.1% avg upside 40 analysts	$170.00 37.81% Downside	+9.8%	·
NMRA Neumora Therapeutics, Inc.	Jun 06, 2024	BUY	Strong Buy +1957.6% avg upside 11 analysts	$22.00 5891.24% Upside	-89.7%	·
BMRN BioMarin Pharmaceutical	Jun 04, 2024	BUY	Strong Buy +63.6% avg upside 52 analysts	$130.00 122.20% Upside	-29.1%	·
CRBU Caribou Biosciences	Jun 03, 2024	BUY	Buy +1510.4% avg upside 13 analysts	$17.00 3917.05% Upside	-50.9%	·
CRSP Crispr Therapeutics AG	May 23, 2024	BUY	Buy +45.6% avg upside 41 analysts	$100.00 94.55% Upside	-33.9%	·
SANA Sana Biotechnology	May 13, 2024	BUY	Strong Buy +282.6% avg upside 14 analysts	$14.00 444.71% Upside	-77.3%	·
MLYS Mineralys Therapeutics, Inc.	May 13, 2024	BUY	Strong Buy +150.9% avg upside 12 analysts	$36.00 98.03% Upside	+17.5%	·
LYEL Lyell Immunopharma	May 13, 2024	BUY	Buy +151.1% avg upside 12 analysts	$9.00 18.50% Downside	-83.1%	·
PCVX Vaxcyte	May 10, 2024	BUY	Strong Buy +77.8% avg upside 15 analysts	$101.00 62.81% Upside	-52.2%	·
RANI Rani Therapeutics Holdings	Mar 15, 2024	HOLD	Strong Buy +1444.2% avg upside 10 analysts	—	-54.4%	·
LIANY LianBio Sponsored ADR	Mar 15, 2024	HOLD	Hold +28128.2% avg upside 4 analysts	—	·	·
TYRA Tyra Bioscience	Dec 15, 2023	HOLD	Strong Buy +107.4% avg upside 17 analysts	$15.00 28.84% Downside	+10.7%	·
GSK GlaxoSmithKline	Oct 11, 2023	SELL	Hold -14.7% avg upside 20 analysts	—	-7.3%	·
VAXX Vaxxinity Inc	Sep 29, 2023	HOLD	Strong Buy +10999899.9% avg upside 4 analysts	—	·	·
IPSC Century Therapeutics	Sep 29, 2023	HOLD	Buy +262.2% avg upside 11 analysts	—	-19.5%	·
VIR Vir Biotechnology	Sep 08, 2023	HOLD	Strong Buy +127.7% avg upside 16 analysts	$14.00 23.93% Upside	-29.4%	·
JANX Janux Therapeutics Inc	Jul 18, 2023	BUY	Strong Buy +159.3% avg upside 22 analysts	$25.00 43.03% Upside	+244.7%	·
LQDA Liquidia Technologies	Mar 16, 2023	BUY	Strong Buy +0.7% avg upside 15 analysts	$13.00 71.12% Downside	+116.9%	·
BBIO BridgeBio Pharma	Mar 06, 2023	BUY	Strong Buy +26.0% avg upside 36 analysts	$18.00 75.97% Downside	+78.3%	·
RCUS Arcus Biosciences	Feb 28, 2023	HOLD	Strong Buy +98.9% avg upside 22 analysts	$23.00 26.37% Upside	+5.2%	·
LENZ LENZ Therapeutics	Feb 23, 2023	SELL	Buy +470.0% avg upside 17 analysts	$2.00 34.39% Downside	-17.6%	·
EDIT Editas Medicine	Feb 22, 2023	HOLD	Buy +398.5% avg upside 33 analysts	$16.00 499.28% Upside	-18.7%	·
UTHR United Therapeutics	Feb 22, 2023	SELL	Buy -22.7% avg upside 27 analysts	$150.00 74.99% Downside	+10.7%	·
CYTK Cytokinetics	Feb 17, 2023	HOLD	Strong Buy +43.4% avg upside 36 analysts	$49.00 22.21% Downside	+68.2%	·
INO Inovio Pharmaceuticals	Feb 16, 2023	SELL	Strong Buy +1300.8% avg upside 19 analysts	$24.00 3884.05% Upside	+56.2%	·
BTAIQ Bioxcel Therapeutics	Nov 14, 2022	BUY	Strong Buy +186224.8% avg upside 12 analysts	$44.00 338361.60% Upside	·	·
OMER Omeros	Jun 08, 2022	HOLD	Hold +13.6% avg upside 14 analysts	$4.00 78.28% Downside	+247.2%	·
PMVP PMV Pharmaceuticals	May 18, 2022	BUY	Strong Buy +951.7% avg upside 13 analysts	$62.00 4632.88% Upside	-58.8%	·
ERAS Erasca	May 17, 2022	BUY	Strong Buy +46.4% avg upside 14 analysts	$20.00 39.35% Upside	-53.3%	·
RGNX RegenXBio	Jan 13, 2022	BUY	Strong Buy +389.7% avg upside 25 analysts	$60.00 733.31% Upside	-7.6%	·
PRTA Prothena	Oct 08, 2021	HOLD	Buy +195.2% avg upside 14 analysts	$75.00 785.40% Upside	-21.0%	·
PAAI ParadiumAI Inc	Jun 08, 2021	HOLD	Strong Buy +630.4% avg upside 12 analysts	—	-24.8%	·
LARK Landmark Bancorp	Mar 19, 2021	BUY	Strong Buy +9.9% avg upside 1 analyst	$35.24 9.87% Upside	+3.9%	·
RCKT Rocket Pharmaceuticals	Jan 05, 2021	BUY	Buy +546.4% avg upside 30 analysts	$70.00 2768.84% Upside	-63.7%	·
BCRX BioCryst	Dec 07, 2020	BUY	Strong Buy +113.8% avg upside 24 analysts	$9.00 6.32% Upside	+69.1%	·
DMRA Damora Therapeutics	Nov 23, 2020	BUY	Strong Buy +39.9% avg upside 20 analysts	$21.00 2.32% Downside	-82.8%	·
SGMOQ Sangamo Therapeutics	Sep 08, 2020	BUY	Buy +9563.8% avg upside 16 analysts	$20.00 17141.37% Upside	·	·
QTTB Q32 Bio	Jun 25, 2020	BUY	Buy +523.8% avg upside 28 analysts	$30.00 236.66% Upside	·	·
TVTX Travere Therapeutics	Feb 25, 2020	HOLD	Strong Buy +15.5% avg upside 22 analysts	$19.00 62.30% Downside	+106.2%	·
DE:MRK Merck KGaA	Feb 20, 2020	HOLD	Buy -7.2% avg upside 34 analysts	$80.32 46.83% Downside	+13.5%	·
GOSS Gossamer Bio	Dec 03, 2019	BUY	Buy +1287.3% avg upside 17 analysts	$32.00 208.27% Upside	·	·
INCY Incyte	May 03, 2019	HOLD	Buy -5.9% avg upside 49 analysts	$82.00 31.94% Downside	+17.1%	·
IRWD Ironwood Pharma	May 02, 2019	HOLD	Buy +239.4% avg upside 23 analysts	$13.00 271.46% Upside	-6.1%	·
DBVT DBV Technologies SA - American	Mar 29, 2019	HOLD	Buy +143.7% avg upside 15 analysts	$8.00 15.62% Downside	-48.8%	·
ALEC Alector	Mar 29, 2019	BUY	Buy +370.1% avg upside 15 analysts	$27.00 1121.68% Upside	+21.6%	·
NBIX Neurocrine	Mar 28, 2019	BUY	Strong Buy +27.3% avg upside 37 analysts	$110.00 24.79% Downside	+3.5%	·
CTMX CytomX Therapeutics	Mar 11, 2019	BUY	Strong Buy +361.2% avg upside 21 analysts	$16.00 583.71% Upside	-41.7%	·
TSE:BHC Bausch Health Companies	Feb 20, 2019	BUY	Buy +386.9% avg upside 30 analysts	$43.32 277.75% Upside	+10.5%	·
ALNY Alnylam Pharma	Sep 07, 2017	BUY	Strong Buy +76.3% avg upside 53 analysts	$105.00 36.26% Downside	+50.3%	·
ZYME Zymeworks	Sep 07, 2017	SELL	Strong Buy +18.4% avg upside 26 analysts	$8.00 72.02% Downside	-87.4%	·
ENTA Enanta Pharmaceuticals	Oct 23, 2015	SELL	Buy +206.4% avg upside 17 analysts	$16.00 49.49% Upside	-2.5%	·
AGIO Agios Pharma	Dec 02, 2014	HOLD	Strong Buy +99.0% avg upside 30 analysts	$90.00 194.66% Upside	-34.0%	·
CLF Cleveland-Cliffs	Sep 17, 2012	HOLD	Buy +0.3% avg upside 20 analysts	—	-45.1%	·

🔒 75 more ratings — with price targets, crowd consensus and our measured returns.

Free account unlocks every analyst's full coverage table.

Geoff Meacham — Frequently Asked Questions

How accurate are Geoff Meacham's stock ratings?

Based on the calls 13Foresight could measure, about 57% of Geoff's ratings were profitable over a one-year hold, with an average return of +3.7% per rating, or -74.1% versus the S&P 500. We score every analyst the same way, from historical prices. Each return is measured in the stock's own trading currency, so for non-US listings the S&P 500 comparison leaves out currency moves.

How is Geoff ranked on 13Foresight?

Geoff Meacham is currently ranked #1882 with a 3-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.

Which stocks does Geoff cover?

Geoff most recently has ratings on ABOS, REGN, GILD, LLY, KYMR, BIIB, AMGN, JAZZ, BNTX, MRNA, VRTX, PFE and 68 more. See the full coverage table above for positions, price targets and our measured returns.

Where can I see other analyst ratings?

Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.

Geoff Meacham

Rating Distribution

Welcome to 13Foresight!